TCP
BOLD

Tourbillon Capital Partners’s Audentes Therapeutics, Inc BOLD Stock Holding History

Tourbillon Capital Partners’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-300,487
Closed -$11.5M – 80
2018
Q2 		$11.5M Buy
300,487
+4,733
+2% +$175K 0.44% 55
2018
Q1 		$8.89M Buy
+295,754
New +$10M 0.35% 50

Other funds holding BOLD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Tourbillon Capital Partners's BOLD Position: Q3 2018 in Review

Tourbillon Capital Partners sold out of Audentes Therapeutics, Inc (BOLD) in Q3 2018, closing a stake of 300,487 shares — an estimated $11.5M sold.

Tourbillon Capital Partners first reported a position in BOLD in Q1 2018 and held it in 2 quarters. The position peaked at $11.5M in Q2 2018. 114 funds tracked by Wall St. Rank hold BOLD as of Q3 2018.

  • Tourbillon Capital Partners reported no remaining Audentes Therapeutics, Inc position as of Q3 2018 after selling out during the quarter.
  • Tourbillon Capital Partners sold 300,487 Audentes Therapeutics, Inc shares in Q3 2018, an estimated $11.5M.
  • Tourbillon Capital Partners first reported a position in Audentes Therapeutics, Inc in Q1 2018 and held it in 2 quarters.
  • Tourbillon Capital Partners's Audentes Therapeutics, Inc position peaked at $11.5M in Q2 2018.
  • 114 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q3 2018.

Based on Tourbillon Capital Partners's 13F filing for Q3 2018, filed 14 Nov 2018.